Y resin microspheres for the treatment of uveal melanoma with liver metastasis: a phase I trial -...

Y resin microspheres for the treatment of uveal melanoma with liver metastasis: a phase I trial  Nature

Final Results of CARES-310 Study: Camrelizumab + Rivoceranib vs Sorafenib in Unresectable HCC - O...

Final Results of CARES-310 Study: Camrelizumab + Rivoceranib vs Sorafenib in Unresectable HCC  Oncodaily

Camrelizumab Plus Rivoceranib vs Sorafenib for the First-Line Treatment of Unresectable Hepatocel...

Camrelizumab Plus Rivoceranib vs Sorafenib for the First-Line Treatment of Unresectable Hepatocellular Carcinoma  The ASCO Post

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable...

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial  The Lancet

Fluorinated Proteolysis Targeting Chimeras-Sorafenib Nanoassembly for Epigenetic Remodeling to Co...

Fluorinated Proteolysis Targeting Chimeras-Sorafenib Nanoassembly for Epigenetic Remodeling to Combat Multi-Pathway Drug Resistance in Hepatocellular Carcinoma  ACS Publications

Cost-effectiveness analysis of toripalimab plus bevacizumab versus sorafenib as first-line treatm...

Cost-effectiveness analysis of toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China  Frontiers

Synergistic antitumor activity of sorafenib and the NUPR1 inhibitor LZX-2-73 in multiple cancer m...

Synergistic antitumor activity of sorafenib and the NUPR1 inhibitor LZX-2-73 in multiple cancer models  Nature

Sorafenib (Nexavar): What patients need to know? - Oncodaily

Sorafenib (Nexavar): What patients need to know?  Oncodaily

Mechanisms of sorafenib-induced cardiotoxicity: ER stress induces upregulation of ATF3, leading t...

Mechanisms of sorafenib-induced cardiotoxicity: ER stress induces upregulation of ATF3, leading to downregulation of NDUFS1 expression and mitochondrial dysfunction  Frontiers

Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immun...

Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma  Nature

LEVIATHAN Study Results: Lenvatinib vs Sorafenib as 2L Treatment for Hepatocellular Carcinoma - O...

LEVIATHAN Study Results: Lenvatinib vs Sorafenib as 2L Treatment for Hepatocellular Carcinoma  Oncodaily

D-lactate and glycerol as potential biomarkers of sorafenib activity in hepatocellular carcinoma ...

D-lactate and glycerol as potential biomarkers of sorafenib activity in hepatocellular carcinoma  Nature

ZEB1 stratifies the response to Sorafenib and Mdivi-1 combination therapy in hepatocellular carci...

ZEB1 stratifies the response to Sorafenib and Mdivi-1 combination therapy in hepatocellular carcinoma  Nature

LINC00162 silencing enhances sorafenib sensitivity and inhibits thyroid cancer cells progression ...

LINC00162 silencing enhances sorafenib sensitivity and inhibits thyroid cancer cells progression through modulation of MAPK signaling and apoptosis  Nature

MOF enhances the sensitivity and selectivity of sorafenib as an anticancer drug against hepatocel...

MOF enhances the sensitivity and selectivity of sorafenib as an anticancer drug against hepatocellular carcinoma and colorectal cancer in vitro  Nature

Matrix stiffness regulates glucose-6-phosphate dehydrogenase expression to mediate sorafenib resi...

Matrix stiffness regulates glucose-6-phosphate dehydrogenase expression to mediate sorafenib resistance in hepatocellular carcinoma through the ITGB1-PI3K/AKT pathway  Nature

SLC25A39 regulates Hedgehog signaling to promote tumor progression and sorafenib resistance in he...

SLC25A39 regulates Hedgehog signaling to promote tumor progression and sorafenib resistance in hepatocellular carcinoma  Nature

Targeting SIX2 as a novel sensitization strategy of sorafenib treatment on advanced hepatocellula...

Targeting SIX2 as a novel sensitization strategy of sorafenib treatment on advanced hepatocellular carcinoma through modulating METTL9-SLC7A11 axis  Nature

Comparative analysis of bevacizumab and sorafenib on the survival of retinal ganglion cells in th...

Comparative analysis of bevacizumab and sorafenib on the survival of retinal ganglion cells in the treatment of retinal diseases  Nature

Vitamin B17 alleviates Sorafenib-induced cardiotoxicity in Ehrlich Ascites Carcinoma mice via mod...

Vitamin B17 alleviates Sorafenib-induced cardiotoxicity in Ehrlich Ascites Carcinoma mice via modulation of inflammatory and fibrotic pathways  Nature

Combined downregulation of TGF-β1 and GRP78 is responsible for overcoming acquired sorafenib resi...

Combined downregulation of TGF-β1 and GRP78 is responsible for overcoming acquired sorafenib resistance, which is initiated by rewiring the cell surface CD44-GRP78-IGF-1R signaling circuit | Cancer Gene Therapy  Nature

Paris court invalidates crucial claim of Bayer’s sorafenib patent - JUVE Patent

Paris court invalidates crucial claim of Bayer’s sorafenib patent  JUVE Patent

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer - 2 Minu...

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer  2 Minute Medicine

Targeting MCM10 disrupts cancer stemness and counteracts sorafenib resistance in hepatocellular c...

Targeting MCM10 disrupts cancer stemness and counteracts sorafenib resistance in hepatocellular carcinoma  Nature

Fluorinated Proteolysis Targeting Chimeras-Sorafenib Nanoassembly for Epigenetic Remodeling to Co...

Fluorinated Proteolysis Targeting Chimeras-Sorafenib Nanoassembly for Epigenetic Remodeling to Combat Multi-Pathway Drug Resistance in Hepatocellular Carcinoma  ACS Publications

From Sorafenib to Precision Medicine: The Future of Systemic Therapy in Hepatocellular Carcinoma ...

From Sorafenib to Precision Medicine: The Future of Systemic Therapy in Hepatocellular Carcinoma  ASCO Daily News

Inhibition of Wnt/β-catenin increases anti-tumor activity by synergizing with sorafenib in hepato...

Inhibition of Wnt/β-catenin increases anti-tumor activity by synergizing with sorafenib in hepatocellular carcinoma  Nature

CSF3R-AS promotes hepatocellular carcinoma progression and sorafenib resistance through the CSF3R...

CSF3R-AS promotes hepatocellular carcinoma progression and sorafenib resistance through the CSF3R/JAK2/STAT3 positive feedback loop  Nature

Pifithrin-μ sensitizes mTOR-activated liver cancer to sorafenib treatment - Nature

Pifithrin-μ sensitizes mTOR-activated liver cancer to sorafenib treatment  Nature

NCOA5 induces sorafenib resistance in hepatocellular carcinoma by inhibiting ferroptosis - Nature

NCOA5 induces sorafenib resistance in hepatocellular carcinoma by inhibiting ferroptosis  Nature

Dimethyl fumarate abrogates hepatocellular carcinoma growth by inhibiting Nrf2/Bcl-xL axis and en...

Dimethyl fumarate abrogates hepatocellular carcinoma growth by inhibiting Nrf2/Bcl-xL axis and enhances sorafenib’s efficacy  Nature

Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocell...

Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial  The Lancet

Immune system development-related signature predicts prognosis and sorafenib-treatment resistance...

Immune system development-related signature predicts prognosis and sorafenib-treatment resistance of hepatocellular carcinoma by intergrating machine learning and single-cell analyses  Nature

Tribbles Pseudokinase 3 Converts Sorafenib Therapy to Neutrophil-Mediated Lung Metastasis in Hepa...

Tribbles Pseudokinase 3 Converts Sorafenib Therapy to Neutrophil-Mediated Lung Metastasis in Hepatocellular Carcinoma  Wiley

Anlotinib Plus Penpulimab in First-Line Treatment of Unresectable Hepatocellular Carcinoma - The ...

Anlotinib Plus Penpulimab in First-Line Treatment of Unresectable Hepatocellular Carcinoma  The ASCO Post

PIP5K1A Suppresses Ferroptosis and Induces Sorafenib Resistance by Stabilizing NRF2 in Hepatocell...

PIP5K1A Suppresses Ferroptosis and Induces Sorafenib Resistance by Stabilizing NRF2 in Hepatocellular Carcinoma  Wiley

Ghassan Abou-Alfa: Radiomic Signatures to Estimate Survival in Patients with Advanced HCC Treated...

Ghassan Abou-Alfa: Radiomic Signatures to Estimate Survival in Patients with Advanced HCC Treated with Sorafenib  Oncodaily

Tremelimumab–Durvalumab Combo Extends Survival and Improves Cost-Effectiveness Over Sorafenib in ...

Tremelimumab–Durvalumab Combo Extends Survival and Improves Cost-Effectiveness Over Sorafenib in Unresectable HCC  Pharmacy Times

New Paper Alert: A pilot study on the neurocognitive effect of sorafenib on patients with desmoid...

New Paper Alert: A pilot study on the neurocognitive effect of sorafenib on patients with desmoid tumors  Oncodaily

TMEM166 negatively regulates unfolded protein response to affect hepatocellular carcinoma cell gr...

TMEM166 negatively regulates unfolded protein response to affect hepatocellular carcinoma cell growth and sorafenib resistance  Nature

Transcription factor YBX1 orchestrates drug resistance and tumor progression in HCC - ScienceDire...

Transcription factor YBX1 orchestrates drug resistance and tumor progression in HCC  ScienceDirect.com

Sorafenib-treated Th9 cells exhibit superior anti-tumor effect in lung metastasis - Nature

Sorafenib-treated Th9 cells exhibit superior anti-tumor effect in lung metastasis  Nature

The effect of sorafenib on cognition in patients with desmoid tumor - Oncodaily

The effect of sorafenib on cognition in patients with desmoid tumor  Oncodaily

Medicine International - Spandidos Publications

Medicine International  Spandidos Publications

Study on the mechanism by which Xuanfu Hua Tang increases sensitivity of hepatocellular carcinoma...

Study on the mechanism by which Xuanfu Hua Tang increases sensitivity of hepatocellular carcinoma cells to sorafenib by antagonizing the Notch1 pathway through HIF-2α  Frontiers

NOX1 inhibition sensitizes HCC cells to sorafenib and radiotherapy by modulating ROS-mediated pro...

NOX1 inhibition sensitizes HCC cells to sorafenib and radiotherapy by modulating ROS-mediated programmed cell death  Nature

Sameer Rastogi Shared Early Results from SORASTOP Trial on Discontinuing Sorafenib in Desmoid Tum...

Sameer Rastogi Shared Early Results from SORASTOP Trial on Discontinuing Sorafenib in Desmoid Tumors  Oncodaily

Circulating mitochondrial DNA promotes M2 polarization of tumor associated macrophages and HCC re...

Circulating mitochondrial DNA promotes M2 polarization of tumor associated macrophages and HCC resistance to sorafenib  Nature

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for patients with unresectab...

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for patients with unresectable hepatocellular carcinoma: a cost–utility analysis in China and the United States  Frontiers

Clinical Profile and Outcome of Patients With Advanced Hepatocellular Carcinoma (HCC) Taking Sora...

Clinical Profile and Outcome of Patients With Advanced Hepatocellular Carcinoma (HCC) Taking Sorafenib or Lenvatinib: Real-World Experience From a Low-Middle Resource Country  Cureus

RBMS3-loss impedes TRIM21-induced ubiquitination of ANGPT2 in an RNA-independent manner and drive...

RBMS3-loss impedes TRIM21-induced ubiquitination of ANGPT2 in an RNA-independent manner and drives sorafenib resistance in hepatocellular carcinoma  Nature

APOLLO Trial: OS Benefit with Anlotini Penpulimab in HCC - Oncodaily

APOLLO Trial: OS Benefit with Anlotini Penpulimab in HCC  Oncodaily

Yiviva Presents Phase 2b Results for YIV-906 in Combination - GlobeNewswire

Yiviva Presents Phase 2b Results for YIV-906 in Combination  GlobeNewswire

Nivolumab/Ipilimumab Maintains OS, ORR Benefits in Chinese Patients With Unresectable HCC - OncLive

Nivolumab/Ipilimumab Maintains OS, ORR Benefits in Chinese Patients With Unresectable HCC  OncLive

Combination Therapy Improves Survival in Liver Cancer - EMJ

Combination Therapy Improves Survival in Liver Cancer  EMJ

Severe Reversible Heart Failure Enhanced by Sorafenib Treatment for Hepatocellular Carcinoma - Cu...

Severe Reversible Heart Failure Enhanced by Sorafenib Treatment for Hepatocellular Carcinoma  Cureus

Clinical breakthrough: Five-year survival in patients with unresectable hepatocellular carcinoma ...

Clinical breakthrough: Five-year survival in patients with unresectable hepatocellular carcinoma sets an unprecedented milestone poised to reshape clinical practice  EurekAlert!

Tyrosine kinase inhibitors were well-tolerated among patients with different etiologies of advanc...

Tyrosine kinase inhibitors were well-tolerated among patients with different etiologies of advanced HCC with lower survival in non-viral patients  Nature

Analyzing Nivolumab and Ipilimumab as HCC Therapy - Targeted Oncology

Analyzing Nivolumab and Ipilimumab as HCC Therapy  Targeted Oncology

Arndt Vogel Highlights HEPATORCH Trial Results Comparing Toripalimab Plus Bevacizumab with Sorafe...

Arndt Vogel Highlights HEPATORCH Trial Results Comparing Toripalimab Plus Bevacizumab with Sorafenib in Advanced HCC  Oncodaily

How the chemotherapy drug sorafenib triggers muscle wasting through cell remodeling - Medical Xpress

How the chemotherapy drug sorafenib triggers muscle wasting through cell remodeling  Medical Xpress

Decoding Drug Interactions: Character and Degree of Pharmacokinetic In | DDDT - Dove Medical Press

Decoding Drug Interactions: Character and Degree of Pharmacokinetic In | DDDT  Dove Medical Press

First-Line Immunotherapy Combo Boosts Survival in Unresectable Liver Cancer - MedPage Today

First-Line Immunotherapy Combo Boosts Survival in Unresectable Liver Cancer  MedPage Today

Bayer’s Sorafenib Safety Study: Key Update for Investors - TipRanks

Bayer’s Sorafenib Safety Study: Key Update for Investors  TipRanks

Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma i...

Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagy  Nature

New knowledge of the mechanisms of sorafenib resistance in liver cancer | Acta Pharmacologica Sin...

New knowledge of the mechanisms of sorafenib resistance in liver cancer | Acta Pharmacologica Sinica  Nature

Sorafenib for Advanced and Refractory Desmoid Tumors - The New England Journal of Medicine

Sorafenib for Advanced and Refractory Desmoid Tumors  The New England Journal of Medicine

Autophagy modulation attenuates sorafenib resistance in HCC induced in rats - Nature

Autophagy modulation attenuates sorafenib resistance in HCC induced in rats  Nature

Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors | Experimental & Molec...

Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors | Experimental & Molecular Medicine  Nature

Adding SBRT to sorafenib improves survival in hepatocellular carcinoma patients - News-Medical

Adding SBRT to sorafenib improves survival in hepatocellular carcinoma patients  News-Medical

Sorafenib inhibits LPS-induced inflammation by regulating Lyn-MAPK-NF-kB/AP-1 pathway and TLR4 ex...

Sorafenib inhibits LPS-induced inflammation by regulating Lyn-MAPK-NF-kB/AP-1 pathway and TLR4 expression  Nature

SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glut...

SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase  Nature

Bayer’s Sorafenib Safety Study: A Closer Look at Market Implications - TipRanks

Bayer’s Sorafenib Safety Study: A Closer Look at Market Implications  TipRanks

Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cance...

Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells  Nature

CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1 - Nature

CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1  Nature

Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-...

Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma  Nature

GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition o...

GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis  Nature

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in ...

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells  Nature

Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FL...

Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial  The Lancet

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RES...

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial  The Lancet

3-hydroxyanthranic acid increases the sensitivity of hepatocellular carcinoma to sorafenib by dec...

3-hydroxyanthranic acid increases the sensitivity of hepatocellular carcinoma to sorafenib by decreasing tumor cell stemness  Nature

Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib res...

Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC  Nature

New Paper Alert: Hepatocellular Carcinoma - Stereotactic Body Radiotherapy vs Sorafenib Alone in ...

New Paper Alert: Hepatocellular Carcinoma - Stereotactic Body Radiotherapy vs Sorafenib Alone in the NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial - JAMA Oncology  Oncodaily

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular ...

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial  The Lancet

Oral sorafenib-loaded microemulsion for breast cancer: evidences from the in-vitro evaluations an...

Oral sorafenib-loaded microemulsion for breast cancer: evidences from the in-vitro evaluations and pharmacokinetic studies  Nature

Pharmacokinetic Exposures Associated With Oral Administration of Sorafenib in Dogs With Spontaneo...

Pharmacokinetic Exposures Associated With Oral Administration of Sorafenib in Dogs With Spontaneous Tumors  Frontiers

MCM2 promotes the stemness and sorafenib resistance of hepatocellular carcinoma cells via hippo s...

MCM2 promotes the stemness and sorafenib resistance of hepatocellular carcinoma cells via hippo signaling  Nature

RCN1 induces sorafenib resistance and malignancy in hepatocellular carcinoma by activating c-MYC ...

RCN1 induces sorafenib resistance and malignancy in hepatocellular carcinoma by activating c-MYC signaling via the IRE1α–XBP1s pathway | Cell Death Discovery  Nature

Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III T...

Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial  ASCO Publications

MCL1 inhibition: a promising approach to augment the efficacy of sorafenib in NSCLC through ferro...

MCL1 inhibition: a promising approach to augment the efficacy of sorafenib in NSCLC through ferroptosis induction  Nature

Addition of SBRT to Systemic Therapy May Improve Outcomes in Select Patients With Locally Advance...

Addition of SBRT to Systemic Therapy May Improve Outcomes in Select Patients With Locally Advanced Hepatocellular Carcinoma  The ASCO Post

UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeosta...

UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma | Signal Transduction and Targeted Therapy  Nature

Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial...

Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial  ScienceDirect.com

Case Report: Severe rash/desquamation induced by sorafenib in an uHCC patient and its clinical ma...

Case Report: Severe rash/desquamation induced by sorafenib in an uHCC patient and its clinical management  Frontiers

Reversal of sorafenib resistance in hepatocellular carcinoma: epigenetically regulated disruption...

Reversal of sorafenib resistance in hepatocellular carcinoma: epigenetically regulated disruption of 14-3-3η/hypoxia-inducible factor-1α  Nature

NRG/RTOG 1112: Radiotherapy Added to Sorafenib Improves Survival in Advanced Hepatocellular Carci...

NRG/RTOG 1112: Radiotherapy Added to Sorafenib Improves Survival in Advanced Hepatocellular Carcinoma  The ASCO Post

TRIM21 mediates the synergistic effect of Olaparib and Sorafenib by degrading BRCA1 through ubiqu...

TRIM21 mediates the synergistic effect of Olaparib and Sorafenib by degrading BRCA1 through ubiquitination in TNBC  Nature

The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular ca...

The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma  Nature

Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and acti...

Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition  PNAS

Sorafenib inhibits ossification of the posterior longitudinal ligament by blocking LOXL2-mediated...

Sorafenib inhibits ossification of the posterior longitudinal ligament by blocking LOXL2-mediated vascularization  Nature